3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase NA
1
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Hereditary Sensory and Autonomic Neuropathies
1
Advanced HER2+Breast Cancer
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Alpelisib
×
Clear all
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA